RMC-023

RMC-023 is an investigational **small-molecule SOS1 inhibitor** developed by Revolution Medicines for oncology research. It has been described in preclinical disclosures as a potent, selective, orally bioavailable inhibitor that disrupts the **RAS-SOS1 protein-protein interaction**, thereby preventing SOS1-mediated nucleotide exchange and reducing formation of active GTP-bound RAS. In turn, this suppresses downstream MAPK pathway signaling and inhibits growth of RAS-driven cancer models. Publicly available information indicates that RMC-023 has primarily been presented as an **in vivo tool compound** in preclinical studies rather than as an advanced clinical development candidate, and it has also been referred to as RMC-0331 and RM-023 in secondary sources and reagent catalogs.